Home > Insider Trading > Filing (0001610717-23-000291)

Filing Details

Accession Number:: 0001610717-23-000291
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-09-20 06:23:08
Reporting Period:: 2023-09-19

Accepted Time:: 2023-09-20 06:23:08
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1885522	Neumora Therapeutics Inc.	NMRA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1569248	Kristina Burow	C/O Neumora Therapeutics, Inc. 490 Arsenal Way, Suite 200 Watertown MA 02472		No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-09-19	13,620	$0.00	13,620	No	4	C	Direct
Common Stock	Acquisiton	2023-09-19	684,167	$0.00	684,167	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2023-09-19	1,144,973	$0.00	1,144,973	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2023-09-19	6,895,021	$0.00	12,205,379	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2023-09-19	6,576,400	$0.00	11,886,758	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2023-09-19	2,124,143	$0.00	2,124,143	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2023-09-19	1,500,000	$17.00	3,624,143	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Preferred Stock	Disposition	2023-09-19	13,620	$0.00	13,620	$0.00
Common Stock	Series A-1 Preferred Stock	Disposition	2023-09-19	684,167	$0.00	684,167	$0.00
Common Stock	Series A-1 Preferred Stock	Disposition	2023-09-19	1,144,973	$0.00	1,144,973	$0.00
Common Stock	Series A-2 Preferred Stock	Disposition	2023-09-19	6,895,021	$0.00	6,895,021	$0.00
Common Stock	Series A-2 Preferred Stock	Disposition	2023-09-19	6,576,400	$0.00	6,576,400	$0.00
Common Stock	Series B Preferred Stock	Disposition	2023-09-19	2,124,143	$0.00	2,124,143	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering.
Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. AVP VII LLC Managing Directors each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. The Reporting Person is a managing director at AVP VII LLC and owns an interest in AVP VII LP but does not have voting or investment control over the shares held by ARCH VII.
Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. AVP VIII LLC Managing Directors each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. The Reporting Person is a managing director at AVP VIII LLC and owns an interest in AVP VIII LLC but does not have voting or investment control over the shares held by ARCH VIII Overage.
The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X Committee Members each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any.
Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. AVP XII LLC Committee Members each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any.